Legal Considerations for Implementing AI into a Medical Aesthetics Practice

The artificial intelligence (AI) boom has arrived in medical aesthetics and is not slowing down. From AI-powered imaging platforms that generate predictive before-and-after visuals to intelligent notetaking software and medical record summary tools, practices across the country are rapidly integrating these technologies into their daily operations. The appeal is understandable. AI promises greater efficiency, enhanced patient engagement, and a competitive edge in an increasingly crowded marketplace. However, as with any emerging technology in health care, the legal and regulatory landscape has not kept pace with the speed of adoption. Practices that move too quickly may find themselves on the wrong side of state medical board regulations, consumer protection statutes, and advertising laws.

This article provides a practical legal framework for medical spas and aesthetic practices evaluating the integration of AI technologies into their businesses. This is not an exhaustive assessment, but it addresses 2 of the most important areas of risk of which practitioners should be aware: AI in health care marketing and AI-driven analysis, diagnostic, and documentation tools.

THE USE OF AI IN HEALTH 
CARE MARKETING

Perhaps the most visible application of AI in medical aesthetics is in marketing. AI-generated before-and-after images, virtual try-on tools, and predictive outcome visualizations are becoming standard features offered by technology vendors to aesthetic practices. These tools allow prospective patients to visualize a digitally rendered representation of their potential appearance following a given procedure. The technology is impressive and can be a powerful patient acquisition tool; however, it also introduces a range of legal concerns that practice owners and their marketing teams must carefully consider.

At the core of the issue is a fundamental question: Does an AI-generated image depicting a predicted aesthetic outcome constitute a false or misleading advertisement? The answer, as is often the case in health care law, depends on the jurisdiction. Most states have statutes and medical board regulations governing the advertising of medical services, including aesthetic procedures. Most of these regulations were drafted well before AI-generated imagery was contemplated, and they vary considerably in their specificity and scope. However, the general principle that runs through virtually all of them is that health care advertising must not be false, deceptive, or misleading to a reasonable consumer.

AI-generated before-and-after images present a particular challenge under this standard because they depict results that have not actually been achieved. Unlike traditional before-and-after photographs, which document a real patient’s outcome, AI-generated images are, by definition, speculative. They represent an algorithmic prediction of what a potential outcome might look like rather than a depiction of an actual patient result. If a prospective patient relies on such an image in making a treatment decision and the actual outcome falls short of the digitally rendered prediction, the practice could face claims of deceptive advertising, breach of express or implied warranty, or even medical malpractice predicated on a theory of informed consent violations.

Practices incorporating AI-generated imagery into their marketing should, at a minimum, carefully review the advertising regulations promulgated by their state medical board, as well as any jurisdiction-specific case law interpreting those regulations in the context of digital or predictive imagery. Appropriate disclaimers should accompany any AI-generated visuals, clearly communicating to the viewer that the images are digitally generated simulations and do not represent actual patient results or a guarantee of any particular outcome. Practices should also consult with legal counsel experienced in health care advertising to evaluate whether their specific use case complies with applicable federal and state consumer protection laws, including the Federal Trade Commission Act and its state-level equivalents.

Beyond AI-generated imagery, practices should also exercise caution with other AI-driven marketing tools, including AI chatbots deployed on practice websites and social media platforms. If an AI chatbot provides clinical information, recommends treatments, or makes representations about expected outcomes, the practice may be exposed to liability related to the content of those communications, even if the responses were autonomously generated by the software. The practice, not the technology vendor, will generally bear the regulatory and legal risk associated with patient-facing communications.

AI NOTETAKERS, MEDICAL 
RECORD SUMMARY TOOLS,
AND DIAGNOSTIC TOOLS

AI-powered notetaking tools and medical record summary generators are increasingly being marketed to health care providers as a means of reducing administrative burden and improving workflow efficiency. These tools use natural language processing and machine learning algorithms to listen to patient encounters, transcribe them, and generate structured clinical notes or summaries of existing medical records. The efficiency gains can be significant, particularly in high-volume aesthetic practices, where providers may see dozens of patients per day. However, these tools also carry meaningful legal risks that must be carefully managed.

First, any AI tool that processes patient health information must comply with federal and state privacy laws. Practices should conduct thorough due diligence on any AI vendor to understand how patient data is collected, transmitted, stored, and used. Business associate agreements should be executed where required, and practices should confirm that the vendor’s data handling practices are consistent with the practice’s own cybersecurity and data compliance program.

Second, practices must ensure that clinical staff who use AI notetaking or medical record summary tools understand that these tools are not a substitute for a thorough and independent review of the patient’s medical records. AI-generated summaries may omit relevant clinical details, misinterpret dictated notes, or fail to flag critical information, such as allergies, contraindications, or previous adverse reactions. A provider who relies exclusively on an AI-generated summary in formulating a treatment plan or plan of care without conducting their own comprehensive review of the underlying records is assuming a significant clinical and legal risk. If a patient is harmed as a result of information that was missed or inaccurately summarized by an AI tool, the provider, not the software vendor, will in most circumstances bear the liability.

Practices should implement clear internal policies and training protocols governing the use of AI documentation tools. These policies should expressly state that AI-generated notes and summaries are preliminary tools to assist the provider’s independent clinical judgment and review and are in no way a substitute for a thorough examination of the patient’s records. Staff should be trained on the known limitations of the specific AI tools being used, and quality assurance processes should be established to audit the accuracy of AI-generated documentation on a regular basis.

CONCLUSION

AI offers tremendous potential to enhance both business operations and the patient experience when it comes to medical aesthetics. However, the legal and regulatory frameworks governing health care marketing and clinical documentation remain complex, highly variable across jurisdictions, and largely untested as applied to AI technologies. Practices that are considering the adoption of AI tools should take a measured approach, engaging experienced legal counsel to evaluate the specific technologies being considered, the regulatory environment in which the practice operates, and the internal safeguards necessary to mitigate risk. The goal should not be to avoid AI altogether, but rather to implement it thoughtfully, compliantly, and with a clear understanding of the legal landscape in which these technologies will be deployed.

Disclaimer: The materials and information provided in this article are for informational purposes only and not for the purpose of providing legal advice. The information contained in this article is a brief overview and should not be construed as legal advice or exhaustive coverage of the topics. Readers should contact an attorney to obtain advice with respect to any particular issue or problem. Statements, opinions, and descriptions contained herein are based on general experience of Frier Levitt attorneys practicing in health care law and are not meant to be relied upon by anyone. All product and company names are trademarks or registered trademarks of their respective holders. Any use of such marks is for educational purposes and does not imply any affiliation with or endorsement by them.